Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-217 (Nurulimab + Prolgolimab) vs Prolgolimab in Advanced Melanoma
NCT05732805Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of nurulimab in melanoma (2 arms), sponsored by BIOCAD. Primary endpoint: Progression-Free Survival at 24 months. Started Aug 2022; status: active, not recruiting.
02
Drugs
nurulimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05732805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732805.